# Design Therapeutics, Inc.

**DSGN**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001807120

# None

**No letter**

5 of 13 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $226.2M |
| **Standard universe** | outside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway, thin data, degenerate in...<br>not computable: fortress balance sheet |
| **Inputs computable** | 5 of 13 |
| **Graded from** | filings received through Mar 9, 2026<br>256 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026 |
| **Last close** | $9.33<br>2026-11-19; market equity $597.5M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 9, 2026*

As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, "Design," "our company," "we," "us," and "our" refer to Design Therapeutics, Inc., a Delaware corporation. We are a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC® molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 56.6** | | | | | | |
| Gross profitability | not computable | 32.8% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.6% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (6.5%) | (6.7%) | 56.6 | 756 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 4.9** | | | | | |
| Altman Z double-prime | 15.76 | 0.31 | 4.3 | 705 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (3.61x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 17.14x | 2.68x | 5.5 | 781 | 2025-12-31 |
| **Growth and financing, sleeve percentile 61.2** | | | | | |
| Revenue growth, three-year compound | not computable | 9.6% | | | |
| *four annual observations are required; found 2* | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.1% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 33.9% | | | |
| *one or more required annual facts are missing* | | | | | |
| Asset growth, three years | (12.8%) | 3.2% | 73.1 | 663 | 2025-12-31 |
| Net share issuance, one year | 8.6% | 1.6% | 49.4 | 625 | 2026-03-02 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 3.1 months |
| Thin data | 5 of 13 grade factors are computable; minimum is 7 |
| Degenerate inputs | latest revenue or assets are at or below the $100,000 validity floor |

## What the price implies

*at the 2026-11-19 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 87.6% | (1.7%) | 89 |
| Distance from 52-week high | (41.5%) | (31.7%) | 40 |
| EBIT to enterprise value | not computable | 0.5% | |
| Free cash flow yield | (9.1%) | 0.6% | 30 |
| Book value to price | 0.34 | 0.29 | 55 |
| Sales to price | 0.00 | 0.37 | 0 |
| Composite equity issuance, five years | not computable | 13.5% | |
| Relative strength against the sector, log excess return | 0.46 | (0.19) | 89 |
| Twelve-month failure probability, CHS model | 0.04% | 0.06% | 43 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $15.3M |
| Operating cash flow, four quarters | -$59.3M |
| Months of runway | 3.1 |
| Days since last periodic filing | 16 (10-Q received Nov 4, 2026) |
| Median daily dollar volume, 63 sessions | $5.8M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$69.8M | 2025-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$54.4M | 2025-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 3 | assets | us-gaap:Assets | $226.2M | 2025-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 4 | assets | us-gaap:Assets | $252.1M | 2024-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 5 | current assets | us-gaap:AssetsCurrent | $223.8M | 2025-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $13.1M | 2025-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$297.0M | 2025-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$79.5M | 2025-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 9 | book equity | us-gaap:StockholdersEquity | $212.5M | 2025-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 10 | liabilities | us-gaap:Liabilities | $13.7M | 2025-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 11 | revenue | us-gaap:Revenues | $0 | 2025-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 12 | revenue | us-gaap:Revenues | $0 | 2024-12-31 | 2025-03-10 | 10-K | 25-035910 |
| 13 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $193,000 | 2025-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 14 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$43.1M | 2024-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 15 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $340,000 | 2024-12-31 | 2026-03-09 | 10-K | 26-098491 |
| 16 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$58.6M | 2023-12-31 | 2025-03-10 | 10-K | 25-035910 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $256,000 | 2023-12-31 | 2025-03-10 | 10-K | 25-035910 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$51.3M | 2022-12-31 | 2024-03-19 | 10-K | 24-033492 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $918,000 | 2022-12-31 | 2024-03-19 | 10-K | 24-033492 |
| 20 | assets | us-gaap:Assets | $289.6M | 2023-12-31 | 2025-03-10 | 10-K | 25-035910 |
| 21 | assets | us-gaap:Assets | $341.1M | 2022-12-31 | 2024-03-19 | 10-K | 24-033492 |
| 22 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 61,672,279 | 2026-03-02 | 2026-03-09 | 10-K | 26-098491 |
| 23 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 56,762,678 | 2025-03-06 | 2025-03-10 | 10-K | 25-035910 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.